BHC
ALNY icon

Bull Harbor Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bull Harbor Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
753
+119
+19% +$35.9K 0.04% 490
2026
Q1 		$210K Buy
+634
New +$216K 0.06% 425

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bull Harbor Capital's ALNY Position: Q2 2026 in Review

Bull Harbor Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 19% in Q2 2026, buying an estimated $35.9K and bringing the position to 753 shares worth $227K. The position accounts for 0.04% of the portfolio, ranked #490.

Bull Harbor Capital first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bull Harbor Capital held 753 shares of Alnylam Pharmaceuticals worth $227K as of Q2 2026.
  • Bull Harbor Capital bought 119 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $35.9K.
  • Alnylam Pharmaceuticals made up 0.04% of Bull Harbor Capital's portfolio in Q2 2026, its #490 holding.
  • Bull Harbor Capital first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bull Harbor Capital's 13F filing for Q2 2026, filed 10 Aug 2026.